Transcriptomics profiling from the TN10 study of individuals with stage 2 T1D revealed an early activation of CD8+ T cells following teplizumab administration, which progressively transitioned into regulatory and exhausted effector phenotypes by 18 months (9). Here, CD8A is linked to type 1 diabetes mellitus.